To develop a system to improve and monitor clinical performance in the management of breast cancer patients in one United Kingdom health region. Design: An observational study of the changes brought about by the introduction of new structures to influence clinical practice and monitor change. Setting: North Thames (East) Health region, comprising seven purchasing health authorities and 21 acute hospitals treating breast cancer. Subjects: The multi-disciplinary breast teams in 21 hospitals and an audit sample of 419 (28%) of the breast cancer patients diagnosed in 1992 in the region. Interventions: Evidence-based interventions for changing clinical practice: regional guidelines, senior clinicians acting as 'opinion leaders', audit of quality rather than cost of services, ownership of data by clinicians, confidential feedback to participants and education. Outcome measures: Qualitative measures of organizational and behavioural change. Quantitative measures of clinical outcomes compared to guideline targets and to results from previous studies within this population. Results: Organizational changes included the involvement, participation of and feedback to 16 specialist surgeons and their multidisciplinary teams in 21 hospitals. Regional clinical guidelines were developed in 6 months and the dataset piloted within 9 months. The audit cycle was completed within 2 years. The pilot study led to prospective audit at the end of 2 years for all breast cancers in the region and a 15-fold increase in high quality clinical information for these patients.
Introduction
cancer patients. The system for improving and monitoring clinical practice comprised seven elements as follows. Within the UK, one of the recommendations of the national Expert Advisory Group on Cancer (EAGC) in 1995 was that health purchasers should develop cancer-specific contracts 1, 2 The steering group as part of a re-organization and improvement of cancer The work was steered by a professor of surgery with a services, aiming to provide uniform care for all patients and specialist interest in breast cancer (IT), who chaired the to improve survival. Contracts should include guidelines Clinical Advisory Board described below, and two for the management of the cancer and measures for assessing representatives of health care purchasing bodies (IB, AP). the performance of cancer units. Guidelines and Three health service researchers at the Cancer Registry set performance indicators were not used systematically at that up and co-ordinated the study. time, nor were data suitable for measuring performance collected systematically. There were various sets of guidelines covering different aspects of care, for screened and symptomatic breast cancer. Evidence-based guidelines Clinical Advisory Panel for breast cancer were published in the following year, A multidisciplinary Clinical Advisory Panel developed 1996, by the Clinical Outcomes Group (COG) 3 of the UK regional clinical standards for the management of breast Department of Health.
cancer. The Panel was broad-based with 19 members, Improving the quality of care of cancer patients requires comprising consultant clinicians, nurses and other health not only commitment to high standards but also professionals representing all aspects of the hospital-based measurement against the standards and implementation of breast cancer services: radiology, surgery, pathology, changes in clinical practice. In this study we set out to oncology and patient support. develop a system which would be capable of improving practice across a UK administrative health region with 3.8 million population, which would monitor changes in practice against performance targets, and which would also Guidelines be achievable and sustainable within the resource-limited health service.
Regional clinical guidelines were based mainly on existing national guidelines and authoritative evidence, and fully There is a considerable body of published evidence on the factors which facilitate change in clinicians' practices. [4] [5] [6] [7] referenced. National UK guidelines for the management of breast cancer were reasonably well developed by 1994 Our system to improve clinical performance aimed to incorporate these: the effective factors are guidelines which particularly through the national Breast Screening Programme (BSP). [27] [28] [29] [30] There were published surgical are local rather than national, involvement and ownership by the clinicians, awareness-raising through education, guidelines from the King's Fund, 31 the British Association of Surgical Oncology (BASO) 32 and the British Breast Cancer respected senior colleagues as opinion leaders, regular feedback of results to clinicians and an overall emphasis on Group. 33 There was guidance on oncology from the Joint Council for Clinical Oncology [34] [35] [36] [37] and the Lancet overview; quality rather than cost of care. Consumer pressure may be also effective.
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38,39 and on patient support.
40,41 National guidelines were then only partially evidence-based; the truly evidence-based To ensure comparability across the hospitals in the region, the measurement of clinical performance had to be based breast cancer guidelines from the Clinical Outcomes Group 3 were not available until 1996. on a standard dataset. The cancer registry was used as the central coordinating point, partly because of its neutral
The Clinical Panel was divided into subgroups for each speciality and set quantifiable targets based on findings from position in the health service market, but mainly because cancer registries have experience in the conduct of previous studies and the clinicians' assessment of current performance (see Surgical Guidelines in Table 1 ; the population-based audits for common cancers in the UK, across Europe [22] [23] [24] and in the USA. [25] [26] Retrospective audits minimum target was intended to be achievable, the ideal was the goal to be reached ultimately). of breast cancer management have demonstrated variations in treatments and outcomes between hospitals and surgeons, Over a 3 month period, the Panel took the guidelines and targets through three cycles of discussion, amendment and for patients diagnosed between 5 and 15 years ago. 11, [15] [16] [17] 19 re-circulation, the guidelines were then considered to be a pragmatic consensus view. The Panel members were reminded of the research evidence at each stage. Some issues Materials and methods on which there was no consensus, such as the need for axillary node surgery were excluded because while there was The study commenced in 1994. The regional Cancer Registry (Thames) data showed that about 2000 new breast cancers a BSP standard, there was no comparable BASO guideline for symptomatic disease. The final draft version of the were diagnosed annually in the regional population-base of 3.8 million people in North Thames East region. Treatment regional guidelines is available from the authors. The draft guidelines were widely discussed with surgeons took place mainly in 21 hospitals, including seven screening centres and three non-screening University hospitals and with a special interest in breast cancer, through professional educational structures, district seminars and regional numerous other small units, including many private clinics. There were more than 80 surgeons operating on breast conferences. 5. Post-operative follow-up a. Cases will be reviewed by a multi-disciplinary group (Surgeon, Radiotherapist, Pathologist) prior to follow-up, to confirm the diagnosis and discuss further management 50 100 b. Women will be reviewed in a dedicated multi-disciplinary combined Clinic (Surgeon and Oncologist/ Radiotherapist) within 10-14 days of discharge, to consider adjuvant therapy 50 95 c. Women will be seen at the first follow-up Clinic with a Breast Care Nurse 50 100 d. There should be opportunity for patients to have reconstructive surgery 80 100
References for draft standards: * British Association of Surgical Oncology. Draft Guidelines for the treatment of Symptomatic Breast Disease in the United Kingdom. 1994; †Breast Screening Guidelines.
Clinical involvement and ownership (a) the clinical management of individual patients, (b) infrastructure-the organization and facilities of the unit Wide clinical involvement was facilitated by the NHS Breast and (c) patient support. Three different surveys were used Screening Quality Assurance networks: surgical, to collect these data. The sources of these data were, radiological, pathology and nursing networks existed in the respectively, the patients' case-notes, interview with the region.
breast surgeon and a postal survey of the specialist nurses. Sixteen breast surgeons were the nominated contacts for
The forms for the first survey, Clinical Management, were the 21 acute hospitals. There were 21 breast specialist nurses developed from clinical audit forms in use in individual involved and 11 histopathologists. (The pathologists were hospital units and the form used in the Eurocare study.
14,22
asked to ensure complete registration of breast cancers in The pathology page was based directly on the Breast their Hospital Units, before the sample for audit was taken).
Screening Pathology Form already in use by laboratories. The surgeons and nurses facilitated the audits and helped
The forms were tested on five sets of patients' case-notes. to develop the guidelines.
Ethical permission was obtained from the nine district Research Ethics Committees, seven of whom passed the Measurement and audit study on Chairman's action without committee discussion. The Clinical Management audit was piloted in 1994-95 The audit set out to measure practice and services against the guideline standards. The guidelines covered three areas: using a retrospective sample of patients diagnosed in 1992.
A stratified design was used to explore differences between hospital types. A stratified random sample of all patients diagnosed in 1992 in the area was taken. A sample size of 50 patients in each strata was required for a statistical power of 80% to detect differences of 20% between hospital types, with a 95% significance level. Hospitals were categorized by type, according to volume (or caseload), that is the total number of new breast cancer patients diagnosed in 1992 and registered at the cancer registry. There were four categories of hospital volume: high (>99 patients per year), medium (50-99), low (11-49) and very low (<10). The (three) non-screening University hospitals were considered as a separate category because of their research activity and different case-mix. For each patient in the random sample, data were abstracted from hospital case-notes by two researchers from the cancer registry and input to a central database. The data analysis comprised a comparison between the regional guideline targets and actual care and services in the region, according to hospital type.
The infrastructure survey collected the organizational information about the breast units using a semi-structured interview with the breast surgeon. The questions covered team working, facilities, manpower, protocols and equipment of the breast units. The third survey on Patient Support utilized a postal questionnaire which was developed coded as shown on the y axis and each surgeon was given the code for his/her hospital(s).
Organizational change Feedback of audit results
The study facilitated quite rapid change in the region's Clinical audit data were collected from the case-notes by ability to monitor treatment outcomes against guidelines in researchers from the Cancer Registry and collated centrally a comparable way across the hospital units. The initial for analysis. Comparative results by anonymized hospitals structures-Clinical Advisory Panel and collaboration were produced and fed back to all participating surgeons. between the breast care teams and the cancer An example is given in Figure 1 . Discussion was encouraged registry-enabled measurement and audit to be tested right both informally and through local and regional conferences. through the audit cycle within 2 years. Regional draft standards were drawn up by the Clinical Advisory Panel within 6 months, a standard dataset was defined and agreed within 9 months; data collection in Units, data analysis Educational outreach centrally by the Registry, and feedback of results on a The study design included one-to-one contact with region-wide scale were completed within 2 years. individual participants in the Trusts to inform and educate At the end of the 2-year pilot, the 15 purchasing health them about the rationale and conduct of the study, in order authorities in North Thames made participation in the to encourage participation initially and to close the audit prospective audit part of the process of accredition of cancer loop finally. The study team visited each of the 21 hospitals units. The audit was implemented prospectively for all breast and contact surgeons at least once, and most several times, cancers in 29 acute hospital units in 1996/97. 42 They jointly during the 1-year study period. These visits maintained commissioned the Cancer Registry to facilitate involvement and dialogue, and facilitated data collection.
implementation and channelled NHS audit monies to fund the data collection within Units. It was the first regionwide prospective audit of breast cancer in England. The prospective audit now collects data on about 3000 cases per Results year, sufficient to study quality and (later) outcomes in depth. The changes observed during the study period were both organizational and clinical. While the organizational Measurement and audit changes were directly attributable to the study, the causality of the clinical changes cannot be established because the Prior to the audit, only four of the 15 centres were collecting a small and non-standard dataset on their patients; others study interventions were not randomized.
had invested considerable resources in system developments support facilities such as information material and lymphoedema and prosthetics services. The organization which were unsatisfactory. During the pilot phase, an audit database was set up on a PC at the Registry. Copies of the survey duplicated in part the much more detailed work of the Breast Screening QA team. In recognition of this, some program were offered to all participating breast units if they wished to implement audit prospectively in their clinics.
health authorities in the region are now using this team to survey the infrastructures of both screening and During the pilot study, one of the screening centres fully implemented the audit dataset for all breast patients symptomatic services. prospectively, using its own database, and seven centres tested the registry's audit software. Within the first
Confidential feedback prospective year, 14 of the 15 hospital units had fully implemented prospective audit and it took a further year
The confidential feedback packs of results were sent out to implement audit prospectively in all 29 hospital units.
to the 16 contact surgeons. Three surgeons requested a More than half the hospital units used the free software presentation of their results, with interpretation of the provided by the Registry. Significant delays were mainly in comparative data for a local clinical audience. Anonymized finding resources for data collection and input. The pilot results were also presented at regional meetings. study has led to a 15-fold increase in the collection of good quality clinical audit data on breast cancer management in Attitude changes the study area.
While the surgeons in 1994-95 were aware of the BASO guidelines, few were aware of the Calman-Hine Clinical effectiveness recommendations and the changes they implied. The audit The clinical findings of the pilot audit are reported network was helpful in spreading awareness. The surgeons elsewhere. 43, 44 The random stratified sample of patients recognized the importance of knowing their workload comprised 419 (28%) of the 1480 eligible patients. The accurately and being able to substantiate claims of good main clinical findings were that overall in the Region most practice. Consequently the audit, which could have been guideline targets were met. The results suggested that a perceived by surgeons both as an extra workload and as minority of women were under-treated: 15% (95% CI= threatening their position, was seen as a benefit. 6-25%) of the node positive pre-menopausal women did Attitude to the Cancer Registry also changed. Several not receive chemotherapy and 10% (95% CI=6-14%) of clinicians commented that for the first time the Registry patients did not receive radiotherapy after conservative was producing information of relevance to them and to surgery. There were few differences between high and low clinical practice in cancer. A network of clinicians actively volume hospital units. The performance of high-volume working with the cancer registry should improve the units was significantly better in certain respects: the use of completeness, quality and utility of cancer registration. FNA for diagnosis, adequate axillary sampling (more than two nodes excised if sampling was done), and access to a high volume (skilled) surgeon and a specialist breast care Conclusion nurse. All hospital units met the waiting time target that 50% of patients should be seen in hospital within 14 working
The study was designed to set up and test an effective days of GP referral. However, 15% of patients in the region process for monitoring and improving clinical performance. waited more than 5 weeks.
The pilot study demonstrated that a region-wide approach The results of 1992 were compared with those from the by consensus among hospital teams could be implemented Eurocare survey for 1990.
14 There were some improvements quite quickly; clinicians appreciated the benefits of standard between 1990 and 1992, but causality remains unproven. data on clinical outcomes, provided that professional Between 1990 and 1992, the proportion of patients given sensitivities were respected in disseminating the results. chemotherapy rose from 17% to 23%. (Chemotherapy use There are many alternative models that are being in the 1980s was even lower at under 10% 11 ). The use of developed for monitoring clinical performance on a local axillary surgery increased dramatically from 46% to 76%, and regional basis but in our view, the important features the proportion of patients having surgery rose from 83% to are as follows: 95% between 1990 and 1992.
Survival outcomes, based on Registry data over a longer (1) the area should be large enough to contain several hospitals of each type-including oncology centres, high timescale, show an upward trend. The 5-year relative survival rate in Thames 45 increased steadily from 52% for volume units and low volume units-in order to make it relevant to consultants at all types of hospital; patients diagnosed in 1960-64, to 68.7% (95% CI= 68.1-69.3) in 1986-90.
(2) local involvement of and ownership by clinical teams is essential in order for the audit to become self-sustaining The organization survey produced data on the infrastructure of breast cancer services in 1995. We found the in hospitals; (3) the audit must benefit the clinicians-the dataset must semi-structured interview was a rather soft tool. However it revealed that only 12 of the 15 hospital units had a specialist help them in organizing their unit or in managing patients; nurse and only five had a lymphoedema clinic. This was supported by data from the Nurses Survey, which also (4) a standard dataset must be collected in all units with common definitions, codes and training notes; emphasized the lack of resources for important patient (5) in coordination of the study across hospitals a balance of the strategy for high quality clinical information to support clinical effectiveness in NHS cancer care. needs to be found between a prescriptive approach, which can threaten ownership, and a devolved approach, which can lead to fragmentation; (6) truly comparative data are valuable to purchasers and Acknowledgements are best collated by a neutral agency such as a cancer registry.
We would like to thank the R&D directorate of North Thames Regional Health Authority for funding this study; There are several improvements that could be made to all the members of the Clinical Advisory Panel, and the our model. The purchasers of cancer services are important consultants, breast care nurses and professionals involved stakeholders and, subsequent to this pilot study, they became in providing and purchasing breast cancer care throughout more actively involved and funded on-going development.
the region, without whose help this study would have been We would also recommend having representation of family impossible; Professor Julian Peto for advice on the design practitioners and patients on the Panel, to guide the study.
of the study; the Cancer Registry's tumour registrars who Professional networks are extremely helpful-we utilized have assisted in finding case-notes; Dr A. Chouillet and Dr those networks set up for the UK NHS breast screening D. Horton who took part in the study; and the many programme; further networks are needed to involve (a) professionals in public health and in health services research oncologists and (b) cancer data managers more closely.
for their interest in this study and constructive comments. Data on the activity of the specialist nurses was difficult to capture and further development is needed to reliably obtain qualitative and quantitative data in the area of
